# Immune Targeting Systems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immune-targeting-systems

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.its-innovation.com
- Total disclosed funding: $24M
- Latest round: Series A (Feb 17, 2010)
- Investors on record: 4

## About

Immune Targeting Systems is a clinical-stage biopharmaceutical company specializing in developing innovative therapeutics for immune-related disorders, focusing on enhancing treatment efficacy through targeted immune modulation.Immune Targeting Systems, founded in 2003, is headquartered in London, UK. The company specializes in peptide-based therapeutics aimed at immune disorders. In February 2015, Immune Targeting Systems was acquired by Vaxin. The firm has completed a total of 6 deals, with its most recent deal occurring on February 17, 2015. The company raised GBP 8.650 mn in its Series A funding round, which represents the total amount raised. Notable investors include Company Guides, HealthCap, Novartis Venture Fund, and Truffle Capital.Immune Targeting Systems is engaged in developing peptide-based therapeutics aimed at improving treatment outcomes for immune-related health issues. Their focus is on creating effective solutions that enhance immune modulation, targeting markets in North America and Europe where there is a significant demand for advanced therapeutic options.In 2021, Immune Targeting Systems reported a revenue of GBP 111,747. The firm's EBITDA for the year 2022 was GBP -11,561,989, reflecting their ongoing investment into product development and market entry strategies.Immune Targeting Systems plans to expand its product portfolio by introducing new therapeutics in the coming years, although specific product release dates have not been disclosed. The company aims to penetrate additional markets in North America and Europe by leveraging the recent funding of GBP 8.650 mn to support these initiatives. The financial support will bolster their research and development efforts, enhancing their capability to address immune-related disorders more effectively.

## Funding rounds

- Series A, Feb 17, 2010, $14M — HealthCap, Truffle Capital, Novartis Venture Fund, Company Guides
- Series A, Jan 26, 2009, $3.5M — HealthCap, Truffle Capital, Novartis Venture Fund, Company Guides
- Series A, Jul 16, 2007, $7M — HealthCap, Truffle Capital, Novartis Venture Fund, Company Guides

## Investors

- HealthCap — Series A
- Truffle Capital (https://capitalatlas.ai/funds/truffle-capital) — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- Company Guides (https://capitalatlas.ai/funds/company-guides) — Series A